Sunitinib‐Induced Cardiotoxicity Is Mediated by Off‐Target Inhibition of AMP‐Activated Protein Kinase

Tyrosine kinase inhibitors (TKIs) are transforming the treatment of patients with malignancies. One such agent, sunitinib (Sutent, Pfizer, New York, NY, USA), has demonstrated activity against a variety of solid tumors. Sunitinib is “multitargeted,” inhibiting growth factor receptors that regulate b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kerkela, Risto, Woulfe, Kathleen C., Durand, Jean‐Bernard, Vagnozzi, Ronald, Kramer, David, Chu, Tammy F., Beahm, Cara, Chen, Ming Hui, Force, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Inc 2009
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2849142/
https://ncbi.nlm.nih.gov/pubmed/20376335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1752-8062.2008.00090.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados